3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes

Circulation

Volumn 108, Issue 12, 2003, Pages 1506-1513

  Blanco Colio, Luis Miguel ^b   Muñoz García, Begoña ^b   Martín Ventura, Jose Luis ^b   Lorz, Corina ^b   Díaz, Cristina ^b   Hernández, Gonzalo ^b   Egido, Jesús ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b NONE

Author keywords

Apoptosis; Lymphocytes; Molecular biology

Indexed keywords

ATORVASTATIN; C3 EXOTOXIN; EXOTOXIN; FARNESYL DIPHOSPHATE; FARNESYL TRANS TRANSFERASE; FAS LIGAND; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IONOMYCIN; MEVALONIC ACID; PHORBOL ESTER; RHO FACTOR; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MONONUCLEAR CELL; MORTALITY; MOUSE; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADP RIBOSE TRANSFERASES; ANIMALS; BOTULINUM TOXINS; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME INHIBITORS; FAS LIGAND PROTEIN; GENES, DOMINANT; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IONOPHORES; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MEVALONIC ACID; MICE; PHORBOL ESTERS; PROTEIN ISOPRENYLATION; PYRROLES; RHOA GTP-BINDING PROTEIN; SIMVASTATIN; T-LYMPHOCYTES; TRANSFECTION;

EID: 0141615830     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000089086.48617.2B     Document Type: Article

References (27)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Nagata S, Golstein P. The Fas death factor. Science. 1995;267: 1449-1456.
3. Lorz C, Ortiz A, Justo P, et al. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol. 2000;11:1266-1277.
4. Boyle JJ, Bowyer DE, Weissberg PL, et al. Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler Thromb Vasc Biol. 2001;21:1402-1407.
5. Sata M, Walsh K. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J Clin Invest. 1998;102:1682-1689.
6. Cai W, Devaux B, Schaper W, et al. The role of Fas/APO-1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 1997;131:177-186.
7. Geng Y-J, Henderson LE, Levesque EB, et al. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17: 2200-2208.
8. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte. Nature. 1992;357:695-697.
9. Kasibhatla S, Genestier L, Green DR. Regulation of Fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kB. J Biol Chem. 1999;247:987-992.
10. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
12. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
13. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 1996;347: 102-103.
14. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
15. Mackay DJ, Hall A. Rho GTPases. J Biol Chem. 1998;273:20685-20688.
16. Perona R, Montaner S, Saniger L, et al. Activation of the nuclear factor-kappaB by Rho, Cdc42, and Rac-1 proteins. Genes Dev. 1997;11: 463-475.
17. Bustos C, Hernández-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
18. Ortego M, Bustos C, Hernández Presa MA, et al. Atorvastatin reduces NF-kB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261.
19. Essig M, Nguyen G, Prie D, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res. 1998; 83:683-690.
20. Hernández-Perera O, Perez-Sala, Soria E, et al. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 2000; 87:616-622.
21. Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1). J Biol Chem. 1999;274:21926-21931.
22. Martínez-Lorenzo MJ, Alava MA, Anel A, et al. Release of preformed Fas ligand in soluble form is the major factor for activation-induced cell death of Jurkat cells. Immunology. 1996;89:511-517.
23. Lang P, Guizani L, Vitté-Mony I, et al. ADP-ribosylation of the ras-related, GTP-binding protein RhoA inhibits lymphocyte-mediated cytotoxicity. J Biol Chem. 1992;267:11677-11680.
24. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926-933.
25. Scheinder DB, Vassalli G, Wen S, et al. Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 2000;20:298-308.
26. Schaub FJ, Han DKM, Liles WC, et al. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med. 2000;6:790-796.
27. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.